DORIA, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 52.554
AS - Asia 30.863
EU - Europa 16.851
SA - Sud America 5.199
AF - Africa 5.168
Continente sconosciuto - Info sul continente non disponibili 939
OC - Oceania 528
AN - Antartide 1
Totale 112.103
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 49.449
SG - Singapore 9.497
IT - Italia 5.075
CN - Cina 4.813
VN - Vietnam 4.590
HK - Hong Kong 3.230
BR - Brasile 3.091
DE - Germania 1.343
BD - Bangladesh 1.296
FI - Finlandia 1.236
FR - Francia 1.210
NL - Olanda 1.005
IN - India 916
GB - Regno Unito 666
SE - Svezia 590
PL - Polonia 570
RU - Federazione Russa 568
IQ - Iraq 516
UA - Ucraina 494
TR - Turchia 480
CA - Canada 450
AR - Argentina 446
JP - Giappone 407
PK - Pakistan 351
ID - Indonesia 331
PH - Filippine 321
MX - Messico 307
SA - Arabia Saudita 307
ES - Italia 305
ZA - Sudafrica 295
EC - Ecuador 274
CO - Colombia 253
AT - Austria 240
UZ - Uzbekistan 239
IE - Irlanda 228
VE - Venezuela 214
EG - Egitto 206
KR - Corea 195
MA - Marocco 195
MY - Malesia 194
JO - Giordania 192
PY - Paraguay 183
PE - Perù 181
RO - Romania 178
TN - Tunisia 178
AE - Emirati Arabi Uniti 175
JM - Giamaica 175
KE - Kenya 175
CL - Cile 174
TH - Thailandia 174
AO - Angola 172
PS - Palestinian Territory 171
RS - Serbia 170
BJ - Benin 165
CR - Costa Rica 165
ET - Etiopia 161
AZ - Azerbaigian 160
NP - Nepal 158
HN - Honduras 157
TT - Trinidad e Tobago 156
AU - Australia 152
DZ - Algeria 152
KZ - Kazakistan 152
DO - Repubblica Dominicana 151
NI - Nicaragua 151
BE - Belgio 150
IL - Israele 150
CH - Svizzera 149
BG - Bulgaria 147
CY - Cipro 146
GT - Guatemala 144
UY - Uruguay 144
HU - Ungheria 143
AL - Albania 142
IR - Iran 141
AM - Armenia 138
CZ - Repubblica Ceca 135
GR - Grecia 135
BY - Bielorussia 134
CI - Costa d'Avorio 133
LB - Libano 131
LU - Lussemburgo 131
SN - Senegal 131
HR - Croazia 130
PT - Portogallo 129
TJ - Tagikistan 129
BA - Bosnia-Erzegovina 128
KG - Kirghizistan 128
LC - Santa Lucia 127
LV - Lettonia 126
NO - Norvegia 126
XK - ???statistics.table.value.countryCode.XK??? 126
CM - Camerun 125
ME - Montenegro 125
CW - ???statistics.table.value.countryCode.CW??? 124
PA - Panama 123
SK - Slovacchia (Repubblica Slovacca) 122
GH - Ghana 121
MU - Mauritius 121
CV - Capo Verde 120
Totale 105.225
Salva come PNG Salva come JPEG
Città #
Ashburn 5.821
Singapore 5.659
Fairfield 5.428
San Jose 4.776
Woodbridge 3.048
Hong Kong 2.923
Houston 2.578
Chandler 2.290
Seattle 1.922
Cambridge 1.903
Ann Arbor 1.889
Wilmington 1.789
Jacksonville 1.591
Ho Chi Minh City 1.392
Hanoi 1.089
Santa Clara 1.043
Los Angeles 972
Beijing 865
Boardman 841
Princeton 819
New York 624
Helsinki 607
Lauterbourg 574
San Diego 568
Milan 453
Medford 398
Des Moines 376
Munich 325
Rome 325
Padova 321
Nanjing 316
São Paulo 307
Bytom 304
Chicago 267
Da Nang 259
Dallas 229
Baghdad 215
Tashkent 207
Tokyo 203
Buffalo 201
Roxbury 198
Haiphong 188
Dublin 175
Amman 173
Council Bluffs 173
Orem 170
Dong Ket 163
Cotonou 156
Hefei 152
Brooklyn 149
London 145
Managua 145
Warsaw 145
Nairobi 144
Naples 144
Baku 143
Vienna 143
Guangzhou 141
Luanda 140
Frankfurt am Main 139
Dakar 131
Johannesburg 129
Abidjan 128
San José 128
Addis Ababa 124
Castries 123
Montreal 121
Ulan Bator 120
Dushanbe 118
Montevideo 118
Conakry 117
Lahore 116
Bishkek 114
Kampala 114
Phoenix 114
Amsterdam 113
Atlanta 112
Harare 112
Istanbul 112
Panama City 112
Yerevan 112
Jeddah 111
Libreville 110
Nuremberg 110
Podgorica 110
Riga 110
Phnom Penh 108
Lima 106
Kingston 105
Havana 104
Accra 103
Bridgetown 103
Nassau 103
Praia 103
Stockholm 103
Turku 103
Rochester 102
Florence 101
Nouakchott 100
Lusaka 99
Totale 63.325
Salva come PNG Salva come JPEG
Nome #
Adult-Onset Still’s Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options 1.276
ISEV2022 Abstract Book 960
Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study 728
An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations 617
Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity 482
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update 467
Relapses of juvenile idiopathic arthritis in adulthood: A monocentric experience 396
Quantitative imaging by pixel-based contrast-enhanced ultrasound reveals a linear relationship between synovial vascular perfusion and the recruitment of pathogenic IL-17A-F+IL-23+ CD161+ CD4+ T helper cells in psoriatic arthritis joints 381
MicroRNAs in idiopathic inflammatory myopathies: state-of-the-art and future perspectives 373
Ex Vivo Signaling Protein Mapping in T Lymphocytes in the Psoriatic Arthritis Joints 358
Derivation and validation of the SLE Disease Activity Score (SLE-DAS): A new SLE continuous measure with high sensitivity for changes in disease activity 352
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study 331
17-β-estradiol affects BLyS serum levels and the nephritogenic autoantibody network accelerating glomerulonephritis in NZB/WF1 mice. 328
Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus. 319
Erosive hand osteoarthritis: latest findings and outlook 317
Transcriptional network profile on synovial fluid T cells in psoriatic arthritis 314
Anti-SAE antibodies in autoimmune myositis: Identification by unlabelled protein immunoprecipitation in an Italian patient cohort. 314
Cocaine- and Levamisole-Induced Vasculitis: Defining the Spectrum of Autoimmune Manifestations 314
Impact of hypertension on vascular remodeling in patients with psoriatic arthritis 312
Gli anticorpi miosite specifici e miosite associati nelle miopatie infiammatorie idiopatiche: studio sierologico di 46 pazienti. 306
PTX3, Anti-PTX3, and Anti-C1q Autoantibodies in Lupus Glomerulonephritis. 304
Prolonged remission in Caucasian patients with SLE: prevalence and outcomes 292
Impact of hypertension on vascular remodeling in patients with psoriatic arthritis 291
Neurolupus is associated with anti-ribosomal P protein antibodies: an inception cohort study 287
Advances in the Diagnosis and Classification of Systemic Lupus Erythematosus 285
In-Hospital Screening Campaign Against Hepatitis C Could Be Effective for Identifying More Patients Who Still Need Treatment 281
Early disease and low baseline damage predict response to belimumab in patients with systemic lupus erythematosus 281
The interferon in idiopathic inflammatory myopathies: Different signatures and new therapeutic perspectives. A literature review 281
SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients 279
Anti-MDA5 dermatomyositis: an update from bench to bedside 277
Effect of Sustained Clinical Remission on the Risk of Lupus Flares and Impaired Kidney Function in Patients With Lupus Nephritis 276
Anti-dsDNA antibody isotypes in systemic lupus erythematosus: IgA in addition to IgG anti-dsDNA help to identify glomerulonephritis and active disease. 276
Therapy of scleroderma renal crisis: State of the art 276
Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: A two-year prospective observational study. 275
Ketogenic diet improves disease activity and cardiovascular risk in psoriatic arthritis: A proof of concept study 274
Autoinflammation and autoimmunity: Bridging the divide. 273
Grade and location of power Doppler are predictive of damage progression in rheumatoid arthritis patients in clinical remission by anti-tumour necrosis factor α 273
Subclinical myopathy in patients affected with newly diagnosed colorectal cancer at clinical onset of disease: evidence from skeletal muscle biopsies. 268
The olfactory function is impaired in patients with idiopathic inflammatory myopathies. 268
Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis 267
Vascular perfusion kinetics by contrast-enhanced ultrasound are related to synovial microvascularity in the joints of psoriatic arthritis. 265
Acute immunomodulatory changes during controlled ovarian stimulation: evidence from the first trial investigating the short-term effects of estradiol on biomarkers and B cells involved in autoimmunity 263
Belimumab: a step forward in the treatment of systemic lupus erythematosus 263
Pulmonary arterial hypertension in connective tissue disorders: Pathophysiology and treatment 262
An observational multicentre study on the efficacy and safety of assisted reproductive technologies in women with rheumatic diseases. 262
European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance 261
Health-Related Quality of Life in Patients With ANCA-Associated Vasculitis and Sinonasal Involvement: A Single-Center Cross-Sectional Study 259
SERPINB3 delays glomerulonephritis and attenuates the lupus-like disease in lupus murine models by inducing a more tolerogenic immune phenotype 258
Medium-/long-term effects of a specific exercise protocol combined with patient education on spine mobility, chronic fatigue, pain, aerobic fitness and level of disability in fibromyalgia. 257
The clinical features, diagnosis and classification of dermatomyositis. 257
Bisphosphonates in patients with autoimmune rheumatic diseases: Can they be used in women of childbearing age? 257
Autoinflammatory Features in Gouty Arthritis 256
Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients 255
Immunization with pentraxin 3 (PTX3) leads to anti-PTX3 antibody production and delayed lupus-like nephritis in NZB/NZW F1 mice. 254
18F-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography With Magnetic Resonance for Diagnosing Adult-Onset Still's Disease 254
Prevalence, outcome and management of patients with SLE and secondary antiphospholipid antibody syndrome after aPL seroconversion 252
Clinical implications of autoantibody screening in patients with autoimmune myositis. 250
Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission 250
Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study 249
Overlap connective tissue disease syndromes. 248
Self-reported flares are predictors of radiographic progression in rheumatoid arthritis patients in 28-joint disease activity score remission: a 24-month observational study 248
2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus 247
The impact of diet on disease activity in spondyloarthritis: A systematic literature review 246
Clinical Guidelines and Definitions of Autoinflammatory Diseases: Contrasts and Comparisons with Autoimmunity-a Comprehensive Review. 246
Detection of Myositis Autoantibodies by Multi-Analytic Immunoassays in a Large Multicenter Cohort of Patients with Definite Idiopathic Inflammatory Myopathies 244
Assessment of Neuropathic Pain in Erosive Hand Osteoarthritis 242
Dupilumab for refractory chronic rhinosinusitis in eosinophilic granulomatosis with polyangiitis 241
Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study 241
Predictors of response to bDMARDs and tsDMARDs in psoriatic arthritis: a pilot study on the role of musculoskeletal ultrasound 239
Cell stress-response in skeletal muscle myofibers 239
A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. 239
Risk factors of damage in early diagnosed systemic lupus erythematosus: results of the Italian multicentre Early Lupus Project inception cohort 239
Remission in systemic lupus erythematosus: Testing different definitions in a large multicentre cohort 238
Autoantibodies Targeting G-Protein-Coupled Receptors: Pathogenetic, Clinical and Therapeutic Implications in Systemic Sclerosis 236
PRESENCE, GRADE AND LOCATION OF POWER DOPPLER PREDICT PROGRESSION OF RADIOGRAPHIC DAMAGE IN TNFα BLOCKER INDUCED CLINICAL REMISSION IN RHEUMATOID ARTHRITIS PATIENTS 236
Rituximab-associated hypogammaglobulinaemia in ANCA-associated vasculitis and connective tissue diseases: a longitudinal observational study 235
Three years is the minimal effective duration of sustained clinical remission which prevents impaired kidney function and damage accrual in lupus nephritis 234
Pregnancy and vasculitis: A systematic review of the literature. 234
Nailfold avascular score and coronary microvascular dysfunction in systemic sclerosis: A newsworthy association 234
Assessment of patients with idiopathic inflammatory myopathies and isolated creatin-kinase elevation 233
Prognosis of scleroderma renal crisis: a long-term observational study. 233
Cutting Edge Issues in Polymyositis 232
The effect of different durations of remission on damage accrual: results from a prospective monocentric cohort of Caucasian patients 232
Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies 232
Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis 232
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort 232
Systemic sclerosis sine scleroderma: clinical and serological features and relationship with other cutaneous subsets in a large series of patients from the national registry 'SPRING' of the Italian Society for Rheumatology 230
The power of the EUSTAR cohort: key findings to date and implicationsfor management of systemic sclerosis patients 230
Assessment of disease activity and damage in SLE: Are we there yet? 230
Anti-inflammatory and immunosuppressive drugs and reproduction 229
Influence of coping skills on health-related quality of life in patients with systemic lupus erythematosus 229
Antigen preparation for immunological studies in systemic autoimmune diseases 229
COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study 229
Interstitial lung disease with and without progressive fibrosing phenotype in patients with idiopathic inflammatory myopathies: data from a large multicentric cohort 228
The Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses 228
Effect of pathogenic crystals on the production of pro- and anti-inflammatory cytokines by different leukocyte populations 228
Clinical outcomes and predictors of maternal and fetal complications in pregnancies of patients with systemic lupus erythematosus 227
EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs 226
SERPINB3, apoptosis and autoimmunity 226
SERPINB3 expression on B-cell surface in autoimmune diseases and hepatitis C virus-related chronic liver infection 226
Totale 29.340
Salva come PNG Salva come JPEG
Categoria #
all - tutte 314.070
article - articoli 300.141
book - libri 1.021
conference - conferenze 0
curatela - curatele 0
other - altro 279
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.617
Totale 618.128
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20226.569 0 709 752 546 281 490 260 756 332 260 629 1.554
2022/20234.891 1.196 462 98 514 746 597 32 346 544 62 221 73
2023/20243.196 116 346 315 247 216 310 218 137 252 159 408 472
2024/202514.363 109 921 675 579 1.712 440 1.238 1.322 1.183 669 2.223 3.292
2025/202657.032 2.250 4.432 7.858 9.191 4.729 2.375 7.685 4.945 5.802 3.388 2.342 2.035
2026/20273.995 3.292 703 0 0 0 0 0 0 0 0 0 0
Totale 112.103